Skip Navigation

Andrew Hantel, MD

Medical Oncology

Make an Appointment


  • Instructor of Medicine, Harvard Medical School
  • Hospitalist, Department of Medical Oncology, Dana-Farber Cancer Institute
  • Postdoctoral Fellow, Division of Population Science, Dana-Farber Cancer Institute

Clinical Interests

  • Hospital Medicine


Dr. Hantel graduated from Loyola University Chicago Stritch School of Medicine in 2013 and received internal medicine residency and hematology/oncology and medical ethics fellowship training at The University of Chicago. He is a hospitalist in Medical Oncology and is a postdoctoral fellow in the Division of Population Science (PI: Dr. Gregory Abel).

Board Certification:

  • Internal Medicine
  • Medical Oncology


  • The University of Chicago, Hematology/Medical Oncology
  • The University of Chicago, Medical Ethics


  • University of Chicago, Internal Medicine

Medical School:

  • Loyola University Chicago


Dr. Hantel is a postdoctoral fellow in the lab of Dr. Gregory Abel, where he investigates the mechanisms and effects of scarce resource allocation on hematology/oncology patients.

Dr. Hantel’s research focuses on investigating and advancing ethical issues of scarce resource allocation in hematology/oncology through patient-centered health services research methods. His research seeks to incorporate patient and physician perspectives into topical ethical dilemmas, thereby informing practice and policy. His recent work employs normative, qualitative, and quantitative approaches to evaluate aspects of the ongoing medication shortage crisis in U.S. hospitals. This work demonstrated the high burden of shortages and medication rationing in hospitals and was published in JAMA Internal Medicine. He is currently examining oncology patient perspectives on shortage management and how different medication shortage allocation models can improve the ability for hospitals to provide needed medications when supplies are limited.

His other research focus is triage and personnel shortages, which are an increasing and understudied problem in subspecialized hematology/oncology care. As advanced care becomes more complex, adequately trained personnel to deliver such care is an increasing barrier to patient access. Dr. Hantel has published a normative ethical framework in the Journal of Medical Ethics evaluating how to justly allocate cellular therapeutics as personnel shortages worsen. His current work is focused on evaluating the current cellular therapy workforce, modeling growth and potential personnel shortages, and working with key stakeholders to improve equitable patient access to care.

Abel GA, Kim HT, Hantel A, Steensma DP, Stone R, Habib A, Ho VT, Wadleigh M, El-Jawahri A, Alyea EP, DeAngelo DJ, Koreth J, Antin JH, Soiffer RJ, Cutler C. Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 Jan 24.
View in: PubMed

Hantel A, Marron JM, Casey M, Kurtz S, Magnavita E, Abel GA. US State Government Crisis Standards of Care Guidelines: Implications for Patients With Cancer. JAMA Oncol. 2020 Dec 03.
View in: PubMed

Hantel A, DuMontier C, Odejide OO, Luskin MR, Sperling AS, Hshieh T, Chen R, Soiffer R, Driver JA, Abel GA. Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment. Cancer. 2020 Nov 25.
View in: PubMed

Abel GA, Kim HT, Hantel A, Steensma DP, Stone R, Habib A, Ho VT, Wadleigh M, El-Jawahri A, Alyea EP, DeAngelo DJ, Koreth J, Antin JH, Soiffer RJ, Cutler C. Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2020 Nov 17.
View in: PubMed

Hantel A, Hlubocky FJ, Siegler M, Daugherty CK. A Qualitative Analysis of Oncology Patient Awareness of Medication Shortages and Their Preferences for How Shortages Should Be Managed. JCO Oncol Pract. 2020 Oct; 16(10):e1098-e1111.
View in: PubMed

Hantel A, Abel GA. An Action Plan for Environmentally Sustainable Cancer Care. JAMA Oncol. 2020 04 01; 6(4):469-470.
View in: PubMed

Hantel A, Egan AM, Nguyen TT, DeMartino ES, Hlubocky F, Bastow S, Siegler M, Daugherty CK. A Cross-Sectional Survey of Medical Trainee Experiences During Medication Shortages. J Grad Med Educ. 2020 Feb; 12(1):38-43.
View in: PubMed

Balagopal V, Hantel A, Kadri S, Steinhardt G, Zhen CJ, Kang W, Wanjari P, Ritterhouse LL, Stock W, Segal JP. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS One. 2019; 14(10):e0224097.
View in: PubMed

Hantel A, Abel GA, Siegler M. Practical allocation system for the distribution of specialised care during cellular therapy access scarcity. J Med Ethics. 2019 08; 45(8):532-537.
View in: PubMed

Hantel A, Siegler M, Hlubocky F, Colgan K, Daugherty CK. Prevalence and Severity of Rationing During Drug Shortages: A National Survey of Health System Pharmacists. JAMA Intern Med. 2019 05 01; 179(5):710-711.
View in: PubMed

Hantel A, Larson RA. Imatinib is still recommended for frontline therapy for CML. Blood Adv. 2018 12 26; 2(24):3648-3652.
View in: PubMed

Hantel A, Gabster B, Cheng JX, Golomb H, Gajewski TF. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018 07 16; 6(1):73.
View in: PubMed

Hantel A, Levine S, Siegler M. Creating Coherent Strategies to Combat the Crises of Opioid Scarcity and Abuse. J Clin Oncol. 2018 09 01; 36(25):2575-2577.
View in: PubMed

Hantel A, Stock W, Kosuri S. Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):636-647.
View in: PubMed

Bestvina CM, Wroblewski KE, Daly B, Beach B, Chow S, Hantel A, Malec M, Huber MT, Polite BN. A Rules-Based Algorithm to Prioritize Poor Prognosis Cancer Patients in Need of Advance Care Planning. J Palliat Med. 2018 06; 21(6):846-849.
View in: PubMed

Khan N, Hantel A, Knoebel RW, Artz A, Larson RA, Godley LA, Thirman MJ, Liu H, Churpek JE, King D, Odenike O, Stock W. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7.
View in: PubMed

Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016 11 24; 375(21):2023-2036.
View in: PubMed

Daly B, Hantel A, Wroblewski K, Balachandran JS, Chow S, DeBoer R, Fleming GF, Hahn OM, Kline J, Liu H, Patel BK, Verma A, Witt LJ, Fukui M, Kumar A, Howell MD, Polite BN. No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. J Oncol Pract. 2016 10; 12(10):e901-e911.
View in: PubMed

Hantel A, Olopade CO. Drug and vaccine access in the Ebola epidemic: advising caution in compassionate use. Ann Intern Med. 2015 Jan 20; 162(2):141-2.
View in: PubMed

Marquez R, Hantel A, Lorenz R, Neistadt B, Wong J, Churpek JE, Mardini NA, Shaukat I, Gurbuxani S, Miller JL, Godley LA. A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk Lymphoma. 2014 Dec; 55(12):2945-6.
View in: PubMed

Hantel A. A protocol and ethical framework for the distribution of rationed chemotherapy. J Clin Ethics. 2014; 25(2):102-15.
View in: PubMed

Nabhan C, Smith SM, Helenowski I, Ramsdale E, Parsons B, Karmali R, Feliciano J, Hanson B, Smith S, McKoy J, Larsen A, Hantel A, Gregory S, Evens AM. Analysis of very elderly (=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol. 2012 Jan; 156(2):196-204.
View in: PubMed

Hantel A, Dick JD, Karp JE. Listeriosis in the setting of malignant disease. Changing issues in an unusual infection. Cancer. 1989 Jul 15; 64(2):516-20.
View in: PubMed


Dana Building
450 Brookline Ave.
Boston, MA 02215
Get Directions